Hikma Pharmaceuticals Plc Directorate Change (6318C)
February 24 2022 - 2:01AM
UK Regulatory
TIDMHIK
RNS Number : 6318C
Hikma Pharmaceuticals Plc
24 February 2022
Hikma Pharmaceuticals PLC - Board and Committee Changes
London, 24 February 2022 - Hikma Pharmaceuticals PLC (LSE: HIK)
(DIFX: HIK) ( Hikma ) announces the following changes to its board
of directors and their responsibilities:
-- Dr. Pamela Kirby has decided not to stand for re-election at
the next annual general meeting of the Company that is scheduled to
take place on 25 April 2022; and
-- Nina Henderson will take over as chair of the Remuneration
Committee with effect from the end of the annual general
meeting.
Said Darwazah, Executive Chairman, said: 'I am very grateful to
Pam for her leadership of the Remuneration Committee and the
considerable value that she has added to the Board, particularly in
relation to her expert knowledge of the pharmaceutical sector. I
wish Pam well for the future. I am pleased that Nina has agreed to
lead the Remuneration Committee going forward. Nina brings to the
role a wealth of remuneration experience and a deep understanding
of Hikma.'
-- ENDS --
Enquiries:
Hikma Pharmaceuticals PLC
Peter Speirs, Company Secretary +44 (0)20 7399 2772
Susan Ringdal, EVP Strategy and Global Affairs +44 (0)20 7399
2760
About Hikma
Hikma helps put better health within reach every day for
millions of people around the world. For more than 40 years, we've
been creating high-quality medicines and making them accessible to
the people who need them. Headquartered in the UK, we are a global
company with a local presence across the United States (US), the
Middle East and North Africa (MENA) and Europe, and we use our
unique insight and expertise to transform cutting-edge science into
innovative solutions that transform people's lives. We're committed
to our customers, and the people they care for, and by thinking
creatively and acting practically, we provide them with a broad
range of branded and non-branded generic medicines. Together, our
8,700 colleagues are helping to shape a healthier world that
enriches all our communities. We are a leading licensing partner,
and through our venture capital arm, are helping bring innovative
health technologies to people around the world. For more
information, please visit: www.hikma.com
(LEI:549300BNS685UXH4JI75)
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
BOAPPUGGPUPPGBW
(END) Dow Jones Newswires
February 24, 2022 02:01 ET (07:01 GMT)
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jun 2024 to Jul 2024
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jul 2023 to Jul 2024